Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.66 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13079103 | 0.86 | ALDH1A1 (0.69) | SIGMAR1ACHEALDH1A1MEN1KMT2A | |
| SCHEMBL14359428 | 0.84 | MEN1 (0.66) | SIGMAR1ALDH1A1MEN1KMT2ACHRNA7 | |
| SCHEMBL13503789 | 0.82 | SIGMAR1 (0.46) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL9595556 | 0.81 | KCNA3 (0.47) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL15151008 | 0.81 | SIGMAR1 (0.45) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL2608082 | 0.80 | SIGMAR1 (0.52) | SIGMAR1ACHEALDH1A1MEN1KMT2A | |
| SCHEMBL12652353 | 0.78 | BACE1 (0.45) | SIGMAR1ACHEMEN1KMT2A | |
| SCHEMBL7142326 | 0.78 | SIGMAR1 (0.47) | SIGMAR1ACHEALDH1A1MEN1KMT2A | |
| SCHEMBL13985382 | 0.78 | SIGMAR1 (0.50) | SIGMAR1ACHEALDH1A1MEN1KMT2A | |
| SCHEMBL23775098 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666865-B2 | for treating pain; STROKES; ANALGESICS; do not contain substituents that are antioxidants, tropolones or coumarins | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-23 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
| US-20090012095-A1 | HUMAN N-TYPE CALCIUM CHANNEL BLOCKERS | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7358251-B2 | N-sulfonylurea apoptosis promoters | ABBOTT LABORATORIES (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070185105-A1 | Calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185105-A1 | Calcium channel blockers | CACNA1S, KCNN4, CACNA1C | SIGMAR1 43/4885ACHE 912/4885ALDH1A1 2714/4885 |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | SIGMAR1 2989/4885ACHE 4701/4885ALDH1A1 2354/4885 |
| US-20090012095-A1 | HUMAN N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1G, CACNA1F | SIGMAR1 949/4885ACHE 814/4885ALDH1A1 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.